Clinical trials = access to tomorrow’s treatments, today. Learn why they could be a powerful part of your cancer journey. Watch now: https://t.co/2yLPSMEqwS #CancerTrials #OncologyResearch #SCRI #HopeCloseToHome

⭐️A 49-year-old man with metastatic germ cell tumor- after exhausting all standard treatments-achieves “complete remission” thanks to allogeneic iNKT cell therapy. ⭐️iNKT =Invariant natural killer T cell therapy 👉🏼A documented first from @BGarmezy & team showcases the power of

Survey-based study of Rx sequencing after 1L EV + P in la/mUC @PriyankaChabla1 @urotoday #GU25 78/227 (34%) response rate, GU Med Oncs Key Q: 2nd line Rx after progression on EV + P? Favor use of: 🖊️PBC w/o combo ICI 🖊️PBC w/o ICI switch maintenance 🖊️Erda in FGFR3-alt

LOXO-435 / FORAGER-1 presented by @IyerGopa at #ASCOGU. FGFR3 specific inhibitor in advanced #bladdercancer with 50% response rate AFTER prior erdafitinib / other FGFRi. Relatively infrequent hyperphos. Exciting news for our FGFR3-altered patients 👏🏻

From our friends at CancerNetwork and PER: 🚨 Oncology Decoded Live at ASCO GU! 📅 Feb 14, 2025, 6–9 PM PT 📍 InterContinental SF & Virtual 🎯 GU cancer experts: Dive into cutting-edge insights for bladder, prostate & RCC care Register now: https://t.co/0qkaWFjp1I

Why do many employed physicians rally behind academic medicine, where prices can soar to 400-600% of Medicare rates? Is it allegiance to the prestige, resources, or something deeper? Meanwhile, private practice docs, who keep healthcare accessible and prices competitive, face

Great conference in Austin, TX bringing together academia and community oncology! Hope to see many of you there @TexasOncology @TheUSONetwork

Decipher® in #mHSPC: Guiding risk assessment and treatment intensification. @AttardLab @ucl joins @Prof_Nick_James @ICR_London discussing findings from the #STAMPEDE trial, focusing on molecular profiling of prostate cancer tumors. #FullVideo on UroToday > https://t.co/rY9qSTqS13

Amazing efforts by ⁦@_ShankarSiva⁩ ⁦@ChadTangMD⁩ at #ASTRO24 putting RCC in the limelight. ⁦With modern day SABR, RCC is not radio-resistance.⁩ ⁦@OncoAlert⁩ ⁦@oncodaily⁩

Dr @dapattmd on Pharmacy Benefit Managers #PBMs and how these behind the scenes actors can influence oncology price. #ASCOQLTY24

I’m hearing so many people cite conflict of interest as the reason physicians shouldn’t own hospitals. This also happens to be the main strategy the American Hospital Association used to lobby Congress to ban POHs in the Affordable Care Act, paving the way for the consolidated

@Uromigos @tompowles1 @brian_rini We look forward to hosting you at the @GUconference next week! There are still a few seats left:

@DavidRSpigel presented important updates from the ADRIATIC study for limited stage #smallcelllungcancer #ASCO24 An exciting day in #lungcancer with results from LAURA study as well as ADRIATIC study, proving again that Today’s Clinical Trials are Tomorrow’s Therapies.

With many FGFR inhibitor agents approved in multiple cancers 👉🏼Management of Adverse Events Associated With FGFR Inhibitors #GI24 #GU24

Cool preclinical study demonstrating synergy between FGFR inhibition and IO via FGFRi-mediated Treg depletion. We’ve seen some early clinical data (NORSE), and would be great to test this hypothesis in larger mUC cohort and with intravesical erdafitinib (TAR-210) in NMIBC

Treatment for muscle invasive bladder cancer will change if the ongoing R3s are +ve. Neoadjuvant IO/ADC combination, bladder sparing approaches, intravesical therapy (TAR200) & ctDNA will improve outcomes and spare patients unnecessary treatments. This is the next chapter IMO.

✴️For NAC-treated patients, ctDNA status was highly prognostic of outcomes. At diagnosis, RFS Hazard Ratio (HR) was 15.6, OS HR 8.9. Post-NAC prior to RC: RFS HR 15.2, OS HR 9. After RC: RFS HR 37.7, OS HR 19.5. ctDNA's predictive power is evident at every stage. #ctDNA

AR degraders showing great activity in patients with #mcrpc and AR LBD mutations at #ESMO23 #ESMO2023. In 878/875mut, psa50 response >50%. Happy that @SarahCannonDocs has been helping develop these novel therapies! @myESMO

Enfortumab vedotin & Pembrolizumab improving PFS & OS by 55% & 53% respectively compared to platinum based chemo in 1st line UC (+avelumab in 30%). Chemo has not been beaten before (despite multiple efforts). RR and CR of 68% & 29% is hard to beat. DOR not reached (1/3)#ESMO2023

Something NEW. TAR-210 releases erdafitinib slowly into the bladder by a novel release system. In BCG refractory FGFR selected High risk NMIBC 82-87% of patients were recurrent free at 1st cut off in the 2 cohort. This could have a major impact in NMIBC and MIBC #ESMO23